ArticleMovement disorders clinical practice
Outcome measures for Parkinson's disease dementia: a systematic review.
Article in Movement disorders clinical practice. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Effectiveness of Inpatient Rehabilitation in Parkinson's Disease: A Systematic Review of Recent Studies.Journal of Parkinson's disease · 2024Pooled it
- An umbrella review of patient- and carer-reported measures for assessing adult end-of-life care quality outcomes.EClinicalMedicine · 2025Article
- Operationalizing goal setting as an outcome measure in trials involving patients with frailty, multimorbidity or complexity.Contemporary clinical trials communications · 2025Article
- An Interdisciplinary Approach to Assistive Technology for Parkinson's Disease Dementia.Clinical interventions in aging · 2025Review
- Mild Behavioral Impairment in Parkinson's Disease: An Updated Review on the Clinical, Genetic, Neuroanatomical, and Pathophysiological Aspects.Medicina (Kaunas, Lithuania) · 2024Review
- Action observation treatment may improve daily living activities and verb recovery in Parkinson's disease-dementia: findings from a preliminary randomized controlled trial.Frontiers in aging neuroscience · 2024Article
- Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations.Translational neurodegeneration · 2022Review
- Treatment of Parkinson's Disease with Cognitive Impairment: Current Approaches and Future Directions.Behavioral sciences (Basel, Switzerland) · 2021Review
- Reconceptualizing Triage to Incorporate Principles of Risk and Uncertainty: An Example from Deep Brain Stimulation Patients with Treatment-Resistant Disorders.The American journal of bioethics : AJOB · 2020Article
- Statistical Considerations for Embedded Pragmatic Clinical Trials in People Living with Dementia.Journal of the American Geriatrics Society · 2020Article
- Measuring quality of life in palliative care for Parkinson's disease: A clinimetric comparison.Parkinsonism & related disorders · 2019Article
- Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.Dementia and geriatric cognitive disorders · 2019Article
- Sleep Apnea Syndrome in an Elderly Population Admitted to a Geriatric Unit: Prevalence and Effect on Cognitive Function.Frontiers in aging neuroscience · 2019Article
- Validation of a performance-based assessment of cognitive functional ability in Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2018Article
- Quantitative susceptibility mapping as an indicator of subcortical and limbic iron abnormality in Parkinson's disease with dementia.NeuroImage. Clinical · 2018Article
- Outcome Measures for Dementia With Lewy Body Clinical Trials: A Review.Alzheimer disease and associated disordersReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundParkinson's disease dementia (PDD) is a major cause of morbidity and mortality in Parkinson's disease (PD), which severely affects patient functioning and quality of life and increases the risk for nursing home admission. Unfortunately, current treatment options for PDD are limited and have only marginal therapeutic effects. As novel treatments are developed, there will be a need to assess their efficacy in well-designed randomized controlled trials. However, there is no consensus on the optimal outcome measures for use in PDD clinical trials.
methodsA systematic review of PDD clinical trials and empiric studies of outcome measures used in PDD was performed. Outcome measures were divided into five categories: 1) cognitive; 2) behavioral and mood; 3) activities of daily living and quality of life; 4) global; and 5) caregiver burden.
findingsA total of 20 PDD pharmacologic clinical trials were identified. These trials incorporated a broad array of outcome measures, which were used inconsistently across trials. We summarize the psychometric properties and other relevant data on outcome measures used, including their diagnostic utility, inter-rater reliability, test-retest reliability, responsiveness, clinically meaningful change, and availability of alternate forms.
conclusionsWe have identified the best-evidenced PDD outcome measures in each domain. Further research is needed to assess the validity, reliability, and clinically meaningful change of these measures in PDD to inform the design of future clinical trials and enhance the ability of clinicians, researchers and policy-makers to interpret study results. In addition, the development of outcome measures specific to PDD may be warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.